
Teva agrees $225 million fee in antitrust case
pharmafile | January 27, 2017 | News story | Medical Communications | Barr Laboratories, Teva, fine
Barr Laboratories, a subsidiary of Teva Pharmaceuticals, has settled an antitrust class action for $225 million. The case relates to a generic version of Bayer’s Cipro, an antibiotic, that was held by Barr Laboratories prior to its purchase by Teva. The case is in regards to ‘pay-to-delay’ cases that have begun to appear more regularly both in the news and the courts.
Bayer had previously settled the case in 2013, for having paid to ensure that the generic was not released onto the market. It has taken over three years for Barr to settle to its part in the deal, where it apparently received $398 million not to market the generic version of Cipro.
The case was brought about by a group of buyers who had purchased Cipro, claiming that the behaviour violated California’s antitrust law and artificially inflated the price of Cipro.
It comes as another financial blow to Teva, which only recently suffered from a $519 million fine for bribery charges across Russia, Ukraine and Mexico. This latest news does not have the same deleterious impact on its reputation, however, as the case dates back prior to the purchase of Barr Laboratories, by Teva, in 2008.
Ben Hargreaves
Related Content

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

Teva’s cancer drug Bendeka protected from generics until 2031, judge rules
A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe …






